Gut bacteria identified in colorectal cancer patients promote tumourigenesis via butyrate secretion/Experiment 3

From BugSigDB


Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10

Curated date: 2022/06/05

Curator: Jeshudy

Revision editor(s): Jeshudy, Claregrieve1, WikiWorks

Subjects

Location of subjects
Japan
Host species Species from which microbiome was sampled. Contact us to have more species added.
Homo sapiens
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Feces Cow dung,Cow pat,Droppings,Dung,Excrement,Excreta,Faeces,Fecal material,Fecal matter,Fewmet,Frass,Guano,Matières fécales@fr,Merde@fr,Ordure,Partie de la merde@fr,Piece of shit,Porción de mierda@es,Portion of dung,Portion of excrement,Portion of faeces,Portion of fecal material,Portion of fecal matter,Portion of feces,Portion of guano,Portion of scat,Portionem cacas,Scat,Spoor,Spraint,Stool,Teil der fäkalien@de,Feces,feces
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Colorectal cancer cancer of colorectum,cancer of large bowel,cancer of large intestine,cancer of the large bowel,colon cancer,colorectal cancer,colorectum cancer,CRC,large intestine cancer,malignant colorectal neoplasm,malignant colorectal tumor,malignant colorectum neoplasm,malignant large bowel neoplasm,malignant large bowel tumor,malignant large intestine neoplasm,malignant large intestine tumor,malignant neoplasm of colorectum,malignant neoplasm of large bowel,malignant neoplasm of large intestine,malignant neoplasm of the large bowel,malignant neoplasm of the large intestine,malignant tumor of large bowel,malignant tumor of large intestine,malignant tumor of the large bowel,malignant tumor of the large intestine,Colorectal cancer
Group 0 name Corresponds to the control (unexposed) group for case-control studies
Healthy Individuals
Group 1 name Corresponds to the case (exposed) group for case-control studies
Patients with advanced CRC
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Patients with early colorectal cancer
Group 0 sample size Number of subjects in the control (unexposed) group
129
Group 1 sample size Number of subjects in the case (exposed) group
153
Antibiotics exclusion Number of days without antibiotics usage (if applicable) and other antibiotics-related criteria used to exclude participants (if any)
1 Month

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V1-V2
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Statistical test
Kruskall-Wallis
Mann-Whitney (Wilcoxon)
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
Yes


Signature 1

Reviewed Marked as Reviewed by Claregrieve1 on 2023/01/10

Curated date: 2022/06/05

Curator: Jeshudy

Revision editor(s): Jeshudy, Claregrieve1

Source: Figure 1B

Description: Differential microbial abundance between advanced CRC patients and healthy controls

Abundance in Group 1: increased abundance in Patients with advanced CRC

NCBI Quality ControlLinks
Alloprevotella tannerae
Dialister pneumosintes
Fusobacterium nucleatum
Gemella morbillorum
Parvimonas micra
Peptostreptococcus anaerobius
Peptostreptococcus stomatis
Porphyromonas asaccharolytica
Porphyromonas gingivalis
Prevotella intermedia
Solobacterium moorei

Revision editor(s): Jeshudy, Claregrieve1